These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 37306706)
1. Temozolomide Sensitizes ARID1A-Mutated Cancers to PARP Inhibitors. Yu ZC; Li T; Tully E; Huang P; Chen CN; Oberdoerffer P; Gaillard S; Shih IM; Wang TL Cancer Res; 2023 Aug; 83(16):2750-2762. PubMed ID: 37306706 [TBL] [Abstract][Full Text] [Related]
2. Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair. Higuchi F; Nagashima H; Ning J; Koerner MVA; Wakimoto H; Cahill DP Clin Cancer Res; 2020 Apr; 26(7):1690-1699. PubMed ID: 31900275 [TBL] [Abstract][Full Text] [Related]
3. Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response. Mandal J; Mandal P; Wang TL; Shih IM J Biomed Sci; 2022 Sep; 29(1):71. PubMed ID: 36123603 [TBL] [Abstract][Full Text] [Related]
4. ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors. Shen J; Peng Y; Wei L; Zhang W; Yang L; Lan L; Kapoor P; Ju Z; Mo Q; Shih IeM; Uray IP; Wu X; Brown PH; Shen X; Mills GB; Peng G Cancer Discov; 2015 Jul; 5(7):752-67. PubMed ID: 26069190 [TBL] [Abstract][Full Text] [Related]
5. ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI). Banerjee S; Stewart J; Porta N; Toms C; Leary A; Lheureux S; Khalique S; Tai J; Attygalle A; Vroobel K; Lord CJ; Natrajan R; Bliss J Int J Gynecol Cancer; 2021 Nov; 31(11):1471-1475. PubMed ID: 34518240 [TBL] [Abstract][Full Text] [Related]
6. Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy. Park Y; Chui MH; Suryo Rahmanto Y; Yu ZC; Shamanna RA; Bellani MA; Gaillard S; Ayhan A; Viswanathan A; Seidman MM; Franco S; Leung AKL; Bohr VA; Shih IM; Wang TL Clin Cancer Res; 2019 Sep; 25(18):5584-5594. PubMed ID: 31196855 [TBL] [Abstract][Full Text] [Related]
7. Targeting ARID1A mutations in cancer. Mullen J; Kato S; Sicklick JK; Kurzrock R Cancer Treat Rev; 2021 Nov; 100():102287. PubMed ID: 34619527 [TBL] [Abstract][Full Text] [Related]
8. PARP inhibitors in the treatment of ARID1A mutant ovarian clear cell cancer: PI3K/Akt1-dependent mechanism of synthetic lethality. Yakovlev VA; Sullivan SA; Fields EC; Temkin SM Front Oncol; 2023; 13():1124147. PubMed ID: 36910637 [TBL] [Abstract][Full Text] [Related]
9. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review. Lau CH; Seow KM; Chen KH Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700 [TBL] [Abstract][Full Text] [Related]
10. ARID1A-mutated ovarian cancers depend on HDAC6 activity. Bitler BG; Wu S; Park PH; Hai Y; Aird KM; Wang Y; Zhai Y; Kossenkov AV; Vara-Ailor A; Rauscher FJ; Zou W; Speicher DW; Huntsman DG; Conejo-Garcia JR; Cho KR; Christianson DW; Zhang R Nat Cell Biol; 2017 Aug; 19(8):962-973. PubMed ID: 28737768 [TBL] [Abstract][Full Text] [Related]
11. CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors. Lu X; He Y; Johnston RL; Nanayakarra D; Sankarasubramanian S; Lopez JA; Friedlander M; Kalimutho M; Hooper JD; Raninga PV; Khanna KK J Exp Clin Cancer Res; 2022 Dec; 41(1):355. PubMed ID: 36539830 [TBL] [Abstract][Full Text] [Related]
12. The Role of the AT-Rich Interaction Domain 1A Gene ( Li JJ; Lee CS Genes (Basel); 2023 Dec; 15(1):. PubMed ID: 38275587 [TBL] [Abstract][Full Text] [Related]
13. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents. Liu L; Taverna P; Whitacre CM; Chatterjee S; Gerson SL Clin Cancer Res; 1999 Oct; 5(10):2908-17. PubMed ID: 10537360 [TBL] [Abstract][Full Text] [Related]
14. ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies. Caumanns JJ; Wisman GBA; Berns K; van der Zee AGJ; de Jong S Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):176-184. PubMed ID: 30025943 [TBL] [Abstract][Full Text] [Related]
15. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations. Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458 [No Abstract] [Full Text] [Related]
16. SN-38 Sensitizes BRCA-Proficient Ovarian Cancers to PARP Inhibitors through Inhibiting Homologous Recombination Repair. Lin S; Tian J; He Q; Yang M; Chen Z; Belogurov AA; Li X; Zhang F; Liu Y; Chen G Dis Markers; 2022; 2022():7243146. PubMed ID: 36267463 [TBL] [Abstract][Full Text] [Related]
18. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness. Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723 [TBL] [Abstract][Full Text] [Related]
19. The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer. Soldi R; Ghosh Halder T; Weston A; Thode T; Drenner K; Lewis R; Kaadige MR; Srivastava S; Daniel Ampanattu S; Rodriguez Del Villar R; Lang J; Vankayalapati H; Weissman B; Trent JM; Hendricks WPD; Sharma S PLoS One; 2020; 15(7):e0235705. PubMed ID: 32649682 [TBL] [Abstract][Full Text] [Related]
20. The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition. Parmar K; Kochupurakkal BS; Lazaro JB; Wang ZC; Palakurthi S; Kirschmeier PT; Yang C; Sambel LA; Färkkilä A; Reznichenko E; Reavis HD; Dunn CE; Zou L; Do KT; Konstantinopoulos PA; Matulonis UA; Liu JF; D'Andrea AD; Shapiro GI Clin Cancer Res; 2019 Oct; 25(20):6127-6140. PubMed ID: 31409614 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]